Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
about
Glucagon and heart in type 2 diabetes: new perspectivesContinued efforts to translate diabetes cardiovascular outcome trials into clinical practiceCurrent perspectives on cardiovascular outcome trials in diabetesStrategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the DiseaseSodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic ReviewIncreased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic KidneysRodent models of diabetic nephropathy: their utility and limitationsClosing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyondType 1 diabetes mellitus.Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease.Medical Management of Diabesity: Do We Have Realistic Targets?Kidney disease and obesity: epidemiology, mechanisms and treatment.Recent advances in CKD and ESRD: A literature update.Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis.Efficacy and Safety of SGLT2 Inhibitors in Reducing Glycated Hemoglobin and Weight in Emirati Patients With Type 2 Diabetes.Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.The impact of antihypertensives on kidney disease.Mechanisms of metabolic memory and renal hypoxia as a therapeutic target in diabetic kidney disease.SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.Modern peptide biomarkers and echocardiography in cardiac healthy haemodialysis patients.Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.EP4 inhibition attenuates the development of diabetic and non-diabetic experimental kidney disease.Sodium-glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusionsOptimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trialsEffects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitusSafety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.Treatment of diabetic kidney disease: current and future targets.A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin.The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysisMechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes.Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study.A Possible Mechanism for Renoprotective Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Elevation of Erythropoietin Production.Gold-quercetin nanoparticles prevent metabolic endotoxemia-induced kidney injury by regulating TLR4/NF-κB signaling and Nrf2 pathway in high fat diet fed mice.Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes.The renal effects of SGLT2 inhibitors and a mini-review of the literature.An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
P2860
Q26738580-AD676B75-01C0-4D90-8478-4DEAF64BA787Q26741860-5C063090-1B02-4289-B7D6-0970516C31ADQ28066006-C5148DAD-3128-4E7A-8E7E-ED9AC70FB0C2Q28069065-363BAAB5-A141-4B81-9729-DADEF9C6030CQ28072352-F51CAFB4-2375-4BE8-A667-8E5115AFD828Q28072939-A49B94D6-2742-4728-A1D7-00BCABF894ABQ28073885-1295C3F0-3190-4752-ACAA-A667EBFE26E0Q28075848-C5D07990-C853-4575-859D-5EED3EEFC53EQ30235021-00CB4598-D60C-4C99-BA7C-525E4DC57CF2Q30235846-206A4E45-53F3-4F24-A21B-3329193D99B1Q30238940-916C957B-4177-48D4-B6CD-8058C8CEAEBFQ30239002-39298AC2-83C1-4CB0-82DF-A999FC173B8BQ30275339-6EAC6BF5-C6BD-4B9C-B888-F6F09175CCEBQ32186373-1F6B88A2-C117-40D7-93EE-1006F4130BC1Q33625207-2B603930-E335-4026-BA60-980C07AD0F47Q33625568-4BCA7ABA-DB9C-4719-BC17-83DD0D9B59B6Q33632021-AE50F4D5-E9ED-47CD-B2B8-EB5E629B8887Q33633674-E7B8928A-CC66-439F-8BCC-CB6C633B857BQ33696974-7C936726-8D8B-467D-A5AE-BE9BA182D0C4Q33743502-84FEC679-7CD3-4EE6-A007-4462FEDB3764Q33781497-A3F1AC5E-CA7E-48FC-BD6E-4084466493CCQ33794256-F6B37141-F7DA-43C8-B87E-6B60C36F62F0Q33820904-58ACD189-0208-475B-AE08-6028713C423CQ33835824-E25987A4-FB85-4A84-B221-AC64725D80DDQ33845734-07D9FE76-EC2C-4B90-8012-629BB1283523Q33871321-F9626DBD-F528-4FE4-8EFD-B733612C90CEQ33890770-A39282D6-3858-4CBA-89F6-9E86DF855DF2Q33907249-3890F6BD-07ED-4534-A687-AE72AAACDDA0Q33913060-02E2485C-4E56-4010-A0CE-867109DAF5DDQ36301818-9E0BBA4C-CE55-4830-B73D-8844550F0802Q36341246-13A57B60-D8BB-4C51-A61F-CFFE26158ABBQ37427304-16F66ADA-5363-4E77-ADC5-386C687284BBQ37559899-34F23D05-1D37-48B2-88B9-7B1E87523E72Q37559907-6AEFA642-36EA-424C-8C1E-6CCE7D2BAB03Q37573794-BFAE4E84-A5DB-43B5-80D6-A22942E02B1EQ37588847-269C03C3-075E-412F-8021-C06A01F34418Q37594479-029CAC58-D1AE-4118-BCD8-50588E786163Q37632127-3BB3C52D-E1FA-4256-B8C7-38483EC95C21Q37661798-0917079C-E6AC-48D2-9D9C-C9D23F791080Q37697744-C428041B-A481-45B3-AEFA-EE4C23F27F19
P2860
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
@en
type
label
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
@en
prefLabel
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
@en
P2093
P50
P356
P1476
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
@en
P2093
Christoph Wanner
David Fitchett
EMPA-REG OUTCOME Investigators
Hans J Woerle
Maximilian von Eynatten
Michaela Mattheus
Silvio E Inzucchi
Uli C Broedl
P304
P356
10.1056/NEJMOA1515920
P407
P577
2016-06-14T00:00:00Z